|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 15S ( Supplement), :
© 2009 American Society of Clinical Oncology
|
Median PFS (mos)
|
HR p-value |
Objective Tumor Response (CR+PR+SD)
|
p-value |
| Pem |
Placebo |
Pem |
Placebo |
|
|
| All patients |
4.3 |
2.6 |
0.502 <0.00001 |
51.7 |
33.3 |
<0.001 |
| Non-squamous (n=482) |
4.5 |
2.6 |
0.444 <0.00001 |
57.7 |
32.7 |
<0.001 |
| Adenocarcinoma (n=329) |
4.7 |
2.6 |
0.452 <0.00001 |
61.0 |
33.0 |
<0.001 |
| Large Cell (n=20) |
3.5 |
2.1 |
0.400 0.109 |
45.5 |
33.3 |
0.670 |
| Other (n=133) |
4.2 |
2.8 |
0.433 0.0002 |
51.1 |
31.7 |
0.041 |
| Squamous (n=181) |
2.8 |
2.6 |
0.692 0.039 |
34.8 |
34.8 |
1.000 |
|
|
